Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 5/20 | 0.73 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5745423 | 0.91 | HTR1A (0.75) | HTR1A | |
| SCHEMBL5744931 | 0.91 | HTR1A (0.75) | HTR1A | |
| SCHEMBL5747759 | 0.91 | HTR1A (0.75) | HTR1A | |
| SCHEMBL5744029 | 0.88 | HTR1A (0.70) | HTR1A | |
| SCHEMBL4779140 | 0.85 | HTR1A (0.98) | HTR1A | |
| SCHEMBL4725440 | 0.83 | HTR1A (0.69) | HTR1A | |
| SCHEMBL4903903 | 0.82 | HTR1A (0.98) | HTR1A | |
| SCHEMBL4778937 | 0.80 | HTR1A (0.58) | HTR1A | |
| SCHEMBL4781752 | 0.80 | HTR1A (0.57) | HTR1A | |
| SCHEMBL4725380 | 0.80 | HTR1A (0.57) | HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351732-B2 | Cycloalkanedione derivatives, method for the production thereof and their pharmacological applications | SCHWARZ PHARMA S.L. (DE) | 2008-04-01 | — | — | US | claimed |
| US-7351732-B2 | Cycloalkanedione derivatives, method for the production thereof and their pharmacological applications | SCHWARZ PHARMA S.L. (DE) | 2008-04-01 | — | — | US | disclosed |
| WO-2008015538-A2 | USE OF DIAZA- AND THIAZA-CYCLOALKANEDIONES FOR PREVENTING AND/OR TREATING PAIN AND /OR MIGRAINE | SCHWARZ PHARMA S.L. (ES) | 2008-02-07 | — | — | WO | disclosed |
| EP-1544201-B1 | NOVEL DERIVATIVES OF CYCLOALCANODIONES, METHOD FOR THE PRODUCTION THEREOF AND THEIR PHARMACOLOGICAL APPLICATIONS | CEPA SCHWARZ PHARMA S L (ES) | 2006-06-28 | — | — | EP | disclosed |
| US-20050250777-A1 | Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications | SCHWARZ PHARMA S.L. (DE) | 2005-11-10 | — | — | US | disclosed |
| EP-1544201-A1 | NOVEL DERIVATIVES OF CYCLOALCANODIONES, METHOD FOR THE PRODUCTION THEREOF AND THEIR PHARMACOLOGICAL APPLICATIONS | Cepa Schwarz Pharma s.l. (ES) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250777-A1 | Novel derivatives of cycloalcanodiones, method for the production thereof and their pharmacological applications | HTR3A, HTR1A, HTR5A | HTR1A 2/4885BCHE 440/4885CHRM2 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.